Search

Your search keyword '"Barritt, A. Sidney"' showing total 98 results

Search Constraints

Start Over You searched for: Author "Barritt, A. Sidney" Remove constraint Author: "Barritt, A. Sidney" Database MEDLINE Remove constraint Database: MEDLINE
98 results on '"Barritt, A. Sidney"'

Search Results

1. Evaluating Disparities in COVID-19 Clinical Outcomes Among Patients With Cirrhosis in North America and Europe-An International Registry Study.

2. Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database.

3. Investigation of the Role of Chemical Analysis in Causality Assessment of Herbal and Dietary Supplement-Induced Liver Injury.

4. High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.

5. Statewide Survey of Primary Care and Subspecialty Providers on Hepatocellular Carcinoma Risk-Stratification and Surveillance Practices.

7. A Yellow Flower With Jaundice Power: Liver Injury Attributed to Greater Celandine.

8. Amiodarone and Dronedarone Causes Liver Injury with Distinctly Different Clinical Presentations.

9. When Is Suspected Drug-Induced Liver Injury (DILI) Not DILI? An Analysis of Unlikely Cases From the Drug-Induced Liver Injury Network.

10. Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study.

11. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.

12. Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010-2018.

13. Liver transplantation from a SARS-COV-2-positive donor: A road ahead or not.

15. Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.

16. Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN].

17. SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes.

18. Hydralazine-Induced Fulminant Liver Failure Requiring Urgent Liver Transplant: Common Drug With Rare Complication.

19. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.

21. Changing opportunities for liver transplant for patients with hepatocellular carcinoma.

22. SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination.

23. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.

24. Early Survivorship After Liver Transplantation: A Qualitative Study Identifying Challenges in Recovery From the Patient and Caregiver Perspective.

25. Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends.

26. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study.

27. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis.

29. What Survivorship Means to Liver Transplant Recipients: Qualitative Groundwork for a Survivorship Conceptual Model.

30. REPLY.

34. SARS-CoV-2 infection in patients with autoimmune hepatitis.

37. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions.

39. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.

40. Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival.

41. Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease.

42. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.

43. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry.

46. A Quality Improvement Initiative Results in Improved Rates of Timely Postvariceal Bleeding Surveillance Endoscopy.

48. Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis.

49. In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge.

50. Rising Mortality From Alcohol-Associated Liver Disease in the United States in the 21st Century.

Catalog

Books, media, physical & digital resources